loading
전일 마감가:
$17.10
열려 있는:
$17.15
하루 거래량:
976.27K
Relative Volume:
0.21
시가총액:
$3.84B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-6.4775
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
-8.07%
1개월 성능:
-53.60%
6개월 성능:
-85.65%
1년 성능:
-88.87%
1일 변동 폭
Value
$16.88
$17.52
1주일 범위
Value
$16.88
$18.88
52주 변동 폭
Value
$16.88
$156.70

사렙타 테라퓨틱스 Stock (SRPT) Company Profile

Name
명칭
Sarepta Therapeutics Inc
Name
전화
617-274-4000
Name
주소
215 FIRST STREET, CAMBRIDGE, MA
Name
직원
1,372
Name
트위터
@sarepta
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
SRPT's Discussions on Twitter

SRPT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
17.45 3.84B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.19 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
526.49 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.93 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
562.46 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.60 28.51B 3.81B -644.79M -669.77M -6.24

사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-16 다운그레이드 BMO Capital Markets Outperform → Market Perform
2025-06-16 다운그레이드 BofA Securities Buy → Neutral
2025-06-16 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-06-16 다운그레이드 H.C. Wainwright Neutral → Sell
2025-06-16 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-06-16 다운그레이드 Piper Sandler Overweight → Neutral
2025-06-06 업그레이드 Scotiabank Sector Perform → Sector Outperform
2025-05-08 다운그레이드 Evercore ISI Outperform → In-line
2025-04-11 개시 Wells Fargo Overweight
2025-04-02 업그레이드 H.C. Wainwright Sell → Neutral
2025-03-31 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2025-02-11 개시 Deutsche Bank Hold
2024-11-27 재확인 Needham Buy
2024-11-25 개시 H.C. Wainwright Sell
2024-11-07 업그레이드 Cantor Fitzgerald Neutral → Overweight
2024-10-21 개시 Jefferies Buy
2024-10-10 재개 Raymond James Outperform
2024-07-29 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2024-06-26 다운그레이드 Citigroup Buy → Neutral
2024-05-31 개시 Piper Sandler Overweight
2024-05-28 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2024-05-14 업그레이드 Oppenheimer Perform → Outperform
2024-01-31 개시 BMO Capital Markets Outperform
2023-12-13 재개 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-21 개시 Wedbush Outperform
2023-10-31 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-10-31 다운그레이드 Oppenheimer Outperform → Perform
2023-06-23 다운그레이드 Evercore ISI Outperform → In-line
2023-04-26 개시 SMBC Nikko Outperform
2023-04-04 개시 Citigroup Buy
2023-03-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-12-22 재확인 BTIG Research Buy
2022-12-16 업그레이드 UBS Neutral → Buy
2022-04-04 재개 Cantor Fitzgerald Overweight
2022-01-05 재확인 Needham Buy
2021-12-09 업그레이드 Oppenheimer Perform → Outperform
2021-11-05 업그레이드 JP Morgan Neutral → Overweight
2021-09-15 업그레이드 Guggenheim Neutral → Buy
2021-08-05 업그레이드 JP Morgan Underweight → Neutral
2021-06-15 개시 BTIG Research Buy
2021-04-26 재개 Credit Suisse Neutral
2021-01-12 다운그레이드 Citigroup Buy → Neutral
2021-01-11 다운그레이드 UBS Buy → Neutral
2021-01-08 다운그레이드 JP Morgan Overweight → Underweight
2021-01-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-01-08 다운그레이드 Raymond James Outperform → Mkt Perform
2020-11-11 개시 Berenberg Hold
2020-10-28 개시 UBS Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 다운그레이드 Credit Suisse Outperform → Neutral
2020-03-31 개시 Mizuho Buy
2019-11-01 개시 Guggenheim Buy
2019-08-21 재확인 Needham Buy
2019-07-09 재확인 Morgan Stanley Overweight
2019-07-01 재확인 RBC Capital Mkts Outperform
2019-04-12 개시 Evercore ISI Outperform
2019-03-11 재확인 Credit Suisse Outperform
2018-10-12 개시 Bernstein Outperform
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-09-26 재확인 RBC Capital Mkts Outperform
2018-09-14 재개 BofA/Merrill Buy
2018-09-06 개시 Credit Suisse Outperform
2018-08-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2018-06-21 재확인 Robert W. Baird Outperform
2018-06-20 재확인 Needham Buy
2018-06-19 재확인 H.C. Wainwright Buy
모두보기

사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스

pulisher
Jun 18, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta stock plunges 42% after second fatal liver failure case - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

From $172 to $20: Sarepta’s Spectacular Fall - Trefis

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly adds highest Zepbound doses to DTC offering - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com

Jun 17, 2025
pulisher
Jun 17, 2025

2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biotech pauses trial after second patient death linked to gene therapy - The Washington Post

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

Jun 16, 2025
pulisher
Jun 16, 2025

Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta shares crash as second patient dies after receiving its gene therapy - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker

Jun 16, 2025
pulisher
Jun 16, 2025

Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg

Jun 16, 2025

사렙타 테라퓨틱스 (SRPT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

사렙타 테라퓨틱스 주식 (SRPT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Barry Richard
Director
May 13 '25
Option Exercise
19.23
20,246
389,359
2,954,317
Nicaise Claude
Director
Mar 12 '25
Option Exercise
25.18
9,746
245,404
30,303
Nicaise Claude
Director
Mar 12 '25
Sale
99.64
2,491
248,203
27,812
$20.63
price down icon 0.27%
$36.10
price up icon 0.04%
$20.82
price down icon 2.33%
$98.53
price down icon 2.05%
$107.07
price up icon 0.55%
biotechnology ONC
$240.30
price down icon 0.62%
자본화:     |  볼륨(24시간):